Sign In
Buy IART
$16.10
+0.430 (+2.74%)
At Close: Jun 03, 2026
Integra (IART) Q2 Revenue Beats by 5%
11:53pm, Thursday, 31'st Jul 2025
Integra (IART) Q2 Revenue Beats by 5%
Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics
10:36am, Thursday, 31'st Jul 2025
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street e
Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates
08:11am, Thursday, 31'st Jul 2025
Integra LifeSciences (IART) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.63 per share a year ago.
Integra LifeSciences Reports Second Quarter 2025 Financial Results
06:00am, Thursday, 31'st Jul 2025
PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the seco
Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025
04:35pm, Monday, 14'th Jul 2025
PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2025 financial re
IART Stock May Rise on First Enrollment in AERA Pediatric Registry
10:26am, Thursday, 03'rd Jul 2025
Integra enrolls first pediatric patient in AERA registry to evaluate real-world use of its ETBD system and expand ENT market presence.
Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry
04:09pm, Wednesday, 02'nd Jul 2025
PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, is proud to announce enrollment of the first pa
NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART). Suc
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
12:35pm, Wednesday, 18'th Jun 2025
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
10:00am, Tuesday, 17'th Jun 2025
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART). Suc
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IAR
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IAR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
09:00am, Thursday, 12'th Jun 2025
NEW YORK , June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART). Suc
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
09:00am, Wednesday, 11'th Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IAR
